BR122020000182B1 - Neurônios dopaminérgicos do mesencéfalo para enxerto - Google Patents

Neurônios dopaminérgicos do mesencéfalo para enxerto

Info

Publication number
BR122020000182B1
BR122020000182B1 BR122020000182A BR122020000182A BR122020000182B1 BR 122020000182 B1 BR122020000182 B1 BR 122020000182B1 BR 122020000182 A BR122020000182 A BR 122020000182A BR 122020000182 A BR122020000182 A BR 122020000182A BR 122020000182 B1 BR122020000182 B1 BR 122020000182B1
Authority
BR
Brazil
Prior art keywords
stem cells
neurons
midbrain
disease
addition
Prior art date
Application number
BR122020000182A
Other languages
English (en)
Other versions
BR122020000182B8 (pt
Inventor
Jae-Won Shim
Lorenz Studer
Sonja Kriks
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR122020000182(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of BR122020000182B1 publication Critical patent/BR122020000182B1/pt
Publication of BR122020000182B8 publication Critical patent/BR122020000182B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Abstract

a presente invenção refere-se ao campo da biologia das células tronco, em particular, a linhagem de diferenciação específica de células tronco pluripotentes ou multipotentes, que podem incluir, mas não se limitam a, células tronco embrionárias humanas (hesc) em adição células tronco pluripotentes induzidas não embrionárias humanas (hipsc), células tronco somáticas, células tronco para pacientes com uma doença, ou qualquer outra célula capaz de diferenciação específica de linhagem. especificamente descritos estão métodos para direcionar a diferenciação específica da linhagem hesc e/ou hipsc em células progenitoras do assoalho do mesencéfalo e, em seguida, além de em grandes populações de neurônios dopaminérgicos (da) foxa2+lmx1a+th+ de destino o mesencéfalo, usando novas condições de cultura. os neurônios dopaminérgicos (da) foxa2+lmx1a+th+ de destino o mesencéfalo feitas utilizando os métodos da presente invenção são ainda contemplado para várias utilizações, incluindo, mas não limitado a, o uso em ensaios in vitro de descoberta de drogas, pesquisa neurologia, e como um agente terapêutico para reverter doença de, ou dano a, uma falta de neurônios dopaminérgicos em um paciente. além disso, as composições e os métodos são fornecidos para diferenciar neurônios dopaminérgicos (da) foxa2+lmx1a+th+ de destino o mesencéfalo a partir de células tronco pluripotentes humanas para uso em modelagem de doenças, em particular a doença de parkinson. além disso, neurônios da autênticos são enriquecidos por marcadores, tais como o cd142 e células neuronais do tipo a9.
BR122020000182A 2011-11-04 2012-11-02 Neurônios dopaminérgicos do mesencéfalo para enxerto BR122020000182B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161555828P 2011-11-04 2011-11-04
BR112014010776-9A BR112014010776B1 (pt) 2011-11-04 2012-11-02 Método in vitro para diferenciação de células tronco pluripotentes
PCT/US2012/063339 WO2013067362A1 (en) 2011-11-04 2012-11-02 Midbrain dopamine (da) neurons for engraftment

Publications (2)

Publication Number Publication Date
BR122020000182B1 true BR122020000182B1 (pt) 2022-04-19
BR122020000182B8 BR122020000182B8 (pt) 2022-05-24

Family

ID=48192829

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122020000182A BR122020000182B8 (pt) 2011-11-04 2012-11-02 Neurônios dopaminérgicos do mesencéfalo para enxerto
BR112014010776-9A BR112014010776B1 (pt) 2011-11-04 2012-11-02 Método in vitro para diferenciação de células tronco pluripotentes

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112014010776-9A BR112014010776B1 (pt) 2011-11-04 2012-11-02 Método in vitro para diferenciação de células tronco pluripotentes

Country Status (16)

Country Link
US (3) US10280398B2 (pt)
EP (2) EP2773748B1 (pt)
JP (6) JP6461602B2 (pt)
KR (4) KR102426327B1 (pt)
CN (5) CN113528442A (pt)
AU (3) AU2012332269B2 (pt)
BR (2) BR122020000182B8 (pt)
CA (2) CA3177246A1 (pt)
DK (1) DK2773748T3 (pt)
EA (1) EA201490796A1 (pt)
ES (1) ES2779453T3 (pt)
HK (1) HK1201879A1 (pt)
IL (4) IL286793B (pt)
PL (1) PL2773748T3 (pt)
PT (1) PT2773748T (pt)
WO (1) WO2013067362A1 (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8642334B2 (en) 2009-02-17 2014-02-04 Memorial Sloan Kettering Cancer Center Methods of neural conversion of human embryonic stem cells
US9487752B2 (en) 2011-03-30 2016-11-08 Cellular Dynamics International, Inc. Priming of pluripotent stem cells for neural differentiation
US10280398B2 (en) * 2011-11-04 2019-05-07 Memorial Sloan-Kettering Cancer Center Midbrain dopamine (DA) neurons for engraftment
CA2910394A1 (en) 2013-04-26 2014-10-30 Memorial Sloan-Kettering Cancer Center Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells
US10017734B2 (en) 2013-08-06 2018-07-10 Takeda Pharmaceutical Company Limited Method for producing dopaminergic neurons
WO2015069736A1 (en) * 2013-11-08 2015-05-14 The Mclean Hospital Corporation METHODS FOR EFFICIENT GENERATION OF GABAergic INTERNEURONS FROM PLURIPOTENT STEM CELLS
US9694036B2 (en) 2014-03-21 2017-07-04 Cellular Dynamics International, Inc. Production of midbrain dopaminergic neurons and methods for the use thereof
WO2015143622A1 (zh) * 2014-03-25 2015-10-01 云南中科灵长类生物医学重点实验室 一种建立神经上皮干细胞的培养基、方法及其应用
WO2016028880A1 (en) 2014-08-19 2016-02-25 Cellular Dynamics International, Inc. Neural networks formed from cells derived from pluripotent stem cells
CN107208045B (zh) 2014-11-25 2018-11-02 宾州研究基金会 人神经胶质细胞转化成用于大脑和脊髓修复的神经细胞的化学重编程
EP3061809B1 (en) 2015-02-27 2019-01-30 Miltenyi Biotec GmbH Method for generation of a cell composition of mesencephalic dopaminergic progenitor cells
US10755078B2 (en) 2015-04-10 2020-08-25 President And Fellows Of Harvard College Methods and devices for live cell imaging analysis
US10081791B2 (en) 2015-05-07 2018-09-25 William J. Freed Modeling connections between dopaminergic neurons and the cerebral cortex
EP3303564B1 (en) * 2015-06-01 2022-02-23 Memorial Sloan Kettering Cancer Center Methods of in vitro differentiation of midbrain dopamine (mda) neurons
CA3001242A1 (en) 2015-10-07 2017-04-13 Memorial Sloan-Kettering Cancer Center In vitro methods of identifying modulators of neuromuscular junction activity
CN105567642B (zh) * 2016-02-01 2019-07-12 中国科学院生物物理研究所 一种着色性干皮病人多能干细胞的制备方法
EP3411048A4 (en) * 2016-02-05 2019-07-31 Memorial Sloan-Kettering Cancer Center METHOD FOR THE DISTINCTION OF PRECURSORS OF STEM CELLS FROM THE ECOTODERMAL DESCALING LINE
US20190117782A1 (en) * 2016-04-05 2019-04-25 The Regents Of The University Of California Cellularized hydrogels and methods of using the same
CN105861532A (zh) * 2016-04-08 2016-08-17 北京大学深圳医院 一种基于miRNA491调节DAT基因表达的方法
KR101870240B1 (ko) * 2016-04-12 2018-06-22 서울대학교산학협력단 지방줄기세포에서 신경줄기세포, 신경세포 및 가바성 신경세포로의 분화 유도 방법
EP3447130A4 (en) * 2016-04-22 2019-11-13 Kyoto University METHOD FOR PRODUCING DOPAMINE-PROPERING NEURAL PRESERVATOR CELLS
KR102487142B1 (ko) 2016-08-16 2023-01-12 후지필름 셀룰러 다이내믹스, 인코포레이티드 만능 세포를 분화시키는 방법
FR3058892B1 (fr) * 2016-11-23 2021-04-09 Univ Bordeaux Unite de tissu neural et utilisation d'une telle unite pour l'implantation dans le systeme nerveux d'un mammifere
CA3057104A1 (en) * 2017-03-21 2018-09-27 Memorial Sloan-Kettering Cancer Center Stem cell-derived astrocytes, methods of making and methods of use
CA3064864A1 (en) * 2017-05-25 2018-11-29 New York Stem Cell Foundation, Inc. Method and composition for generating basal forebrain cholinergic neurons (bfcns)
CN107828728A (zh) * 2017-10-26 2018-03-23 中山大学 一种制备中脑多巴胺神经元的方法
KR102201417B1 (ko) * 2018-05-02 2021-01-11 (주) 에스바이오메딕스 도파민 신경세포의 분리방법 및 이를 이용하여 분리된 도파민 신경세포를 포함하는 파킨슨병 치료용 약제학적 조성물
KR102111030B1 (ko) * 2018-05-10 2020-05-14 한국과학기술원 Jab1을 포함하는 신경세포 분화 탐지용 바이오마커 또는 신경세포 분화 촉진용 조성물
EP3894556A1 (en) * 2018-12-11 2021-10-20 University of Rochester Methods of treating schizophrenia and other neuropsychiatric disorders
CN112011510B (zh) * 2019-05-30 2023-01-03 中国科学院上海有机化学研究所 一种由人多能干细胞制备多巴胺神经元的方法
KR102183208B1 (ko) * 2019-07-25 2020-11-25 한국과학기술연구원 Ngn2(neurogenin-2)를 이용하여 척수 손상 모델에서 반응성 성상세포를 신경세포로 리프로그래밍하는 방법
CA3145700A1 (en) 2019-07-25 2021-01-28 Jeanne F. Loring Methods of identifying dopaminergic neurons and progenitor cells
CN114729323A (zh) * 2019-11-22 2022-07-08 诺和诺德股份有限公司 旋转聚集的神经微球及其应用
US20230293593A1 (en) 2020-03-25 2023-09-21 Sana Biotechnology, Inc. Hypoimmunogenic neural cells for the treatment of neurological disorders and conditions
EP4127137A1 (en) * 2020-04-02 2023-02-08 Memorial Sloan Kettering Cancer Center Methods of generating midbrain dopamine neurons, midbrain neurons and uses thereof
WO2021216623A1 (en) 2020-04-21 2021-10-28 Aspen Neuroscience, Inc. Gene editing of lrrk2 in stem cells and method of use of cells differentiated therefrom
WO2021216622A1 (en) 2020-04-21 2021-10-28 Aspen Neuroscience, Inc. Gene editing of gba1 in stem cells and method of use of cells differentiated therefrom
CN114292814A (zh) * 2020-09-22 2022-04-08 上海跃赛生物科技有限公司 一种多能干细胞分化为中脑黒质多巴胺能神经细胞的方法
AU2022256048A1 (en) 2021-04-07 2023-10-05 FUJIFILM Cellular Dynamics, Inc. Dopaminergic precursor cells and methods of use
CN117500916A (zh) 2021-04-16 2024-02-02 博恩赛尔公司 制备、扩增和纯化中脑多巴胺能祖细胞的方法
CN117202914A (zh) * 2021-04-21 2023-12-08 上海跃赛生物科技有限公司 一种质控和富集人多巴胺能神经前体细胞的方法
CN113388580B (zh) * 2021-06-16 2022-02-18 中国医学科学院医学实验动物研究所 一种诱导脂肪干细胞分化为功能性多巴胺能神经元的方法及用途
CA3223104A1 (en) * 2021-06-18 2022-12-22 Lorenz Studer Methods of generating sacral neural crest lineages and uses thereof
CA3222505A1 (en) * 2021-07-14 2023-01-19 Sang Hun Lee Composition for inhibiting alpha-synuclein aggregation and method for inhibiting alpha-synuclein aggregation
WO2023004371A1 (en) * 2021-07-21 2023-01-26 Aspen Neuroscience, Inc. Methods of differentiating neural cells and predicting engraftment thereof and related compositions
WO2023004370A1 (en) 2021-07-21 2023-01-26 Aspen Neuroscience, Inc. Aav-based modulation of gba1 and related compositions and uses thereof
US20230081881A1 (en) 2021-07-21 2023-03-16 Aspen Neuroscience, Inc. Transposon-based modulation of gba1 and related compositions and uses thereof
CN113481160B (zh) * 2021-08-20 2022-04-29 北京太东生物科技有限公司 视网膜色素上皮细胞诱导培养基及其应用
KR20240055838A (ko) 2021-09-10 2024-04-29 후지필름 셀룰러 다이내믹스, 인코포레이티드 유도된 만능 줄기 세포 유래된 세포의 조성물 및 이의 사용 방법
CN117089520A (zh) * 2021-10-28 2023-11-21 中国科学院动物研究所 一种中脑多巴胺细胞群、其制造方法以及用途
US20240034992A1 (en) 2021-10-29 2024-02-01 FUJIFILM Cellular Dynamics, Inc. Dopaminergic neurons comprising mutations and methods of use thereof
WO2023104792A1 (en) 2021-12-07 2023-06-15 Vib Vzw Enhancers of neuronal maturation
WO2023177919A1 (en) * 2022-03-18 2023-09-21 Memorial Sloan-Kettering Cancer Center Methods and compositions for improving in vivo survival of midbrain dopamine neurons
US20230377685A1 (en) 2022-04-15 2023-11-23 Aspen Neuroscience, Inc. Methods of classifying the differentiation state of cells and related compositions of differentiated cells

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001541A1 (en) 1988-08-04 1990-02-22 Amrad Corporation Limited In vitro propagation of embryonic stem cells
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
US5589376A (en) 1992-07-27 1996-12-31 California Institute Of Technology Mammalian neural crest stem cells
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
US6787356B1 (en) 1998-07-24 2004-09-07 The United States Of America As Represented By The Department Of Health And Human Services Cell expansion system for use in neural transplantation
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US6610540B1 (en) 1998-11-18 2003-08-26 California Institute Of Technology Low oxygen culturing of central nervous system progenitor cells
US20050042749A1 (en) 2001-05-16 2005-02-24 Carpenter Melissa K. Dopaminergic neurons and proliferation-competent precursor cells for treating Parkinson's disease
US7005252B1 (en) 2000-03-09 2006-02-28 Wisconsin Alumni Research Foundation Serum free cultivation of primate embryonic stem cells
US7011828B2 (en) 2000-03-14 2006-03-14 Es Cell International Pte. Ltd. Implanting neural progenitor cells derived for human embryonic stem cells
WO2001068815A1 (en) 2000-03-14 2001-09-20 Es Cell International Pte Ltd Embryonic stem cells and neural progenitor cells derived therefrom
US7250294B2 (en) * 2000-05-17 2007-07-31 Geron Corporation Screening small molecule drugs using neural cells differentiated from human embryonic stem cells
JP5943533B2 (ja) 2000-05-17 2016-07-06 アステリアス バイオセラピューティクス インコーポレイテッド 神経前駆細胞の集団
EP2298867A3 (en) 2000-06-20 2013-01-16 ES Cell International Pte Ltd. Method of controlling differentiation of embryonic stem (ES) cells by culturing ES cells in the presence of bmp-2 pathway antagonists
DE10037759A1 (de) 2000-08-03 2002-07-04 Gruenenthal Gmbh Screeningverfahren
WO2002026941A2 (en) 2000-09-29 2002-04-04 Kooy Derek V D Primitive neural stem cells and method for differentiation of stem cells to neural cells
JP3660601B2 (ja) 2001-03-30 2005-06-15 独立行政法人科学技術振興機構 胚性幹細胞からの神経幹細胞、運動ニューロン及びｇａｂａ作動性ニューロンの製造法
WO2002086073A2 (en) 2001-04-20 2002-10-31 Memorial Sloan-Kettering Cancer Center Generation of differentiated tissue from nuclear transfer embryonic stem cells and methods of use
US20030211605A1 (en) 2001-05-01 2003-11-13 Lee Sang-Hun Derivation of midbrain dopaminergic neurons from embryonic stem cells
US6887706B2 (en) 2001-10-03 2005-05-03 Wisconsin Alumni Research Foundation Method of in vitro differentiation of transplantable neural precursor cells from primate embryonic stem cells
US20040224302A1 (en) 2002-07-16 2004-11-11 Thomas Jessel Systems and methods for screening for modulators of neural differentiation
AU2003250705A1 (en) 2002-07-31 2004-02-16 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
AU2003276924A1 (en) 2002-09-25 2004-04-19 Bresagen, Inc. Compositions and methods for enrichment of neural stem cells using ceramide analogs
AU2003296316A1 (en) 2002-12-09 2004-06-30 The Mclean Hospital Corporation Dopaminergic neurons differentiated from embryonic cells for treating neurodegenerative diseases
US7252995B2 (en) 2002-12-13 2007-08-07 Yu-Show Fu Method of generating neurons from stem cells and medium for culturing stem cells
ZA200401646B (en) * 2003-03-12 2004-06-07 Reliance Life Sciences Pvt Ltd Derivation of terminally differentiated dopaminergic neurons from human embryonic stem cells.
CN1774265A (zh) 2003-04-18 2006-05-17 协和发酵工业株式会社 神经再生药
US7332336B2 (en) 2003-08-19 2008-02-19 Effector Cell Institute, Inc. Methods for inducing differentiation of pluripotent cells
EP1799272A2 (en) 2004-10-05 2007-06-27 Memorial Sloan-Kettering Cancer Center Promotion of cell migration and axon regeneration in the cns
JP5270362B2 (ja) * 2005-11-10 2013-08-21 ジェナボン バイオファーマシューティカルズ エルエルシー 幹細胞のｍｎｔｆ分化および成長
EP1999249B8 (en) 2006-03-30 2012-02-15 The University Court Of The University of Edinburgh Culture medium containing kinase inhibitors. and uses thereof
WO2008018190A1 (fr) 2006-08-09 2008-02-14 Biomaster, Inc. Cellules de la crête neurale dérivées de tissu adipeux
JP2008099662A (ja) 2006-09-22 2008-05-01 Institute Of Physical & Chemical Research 幹細胞の培養方法
GB0622394D0 (en) 2006-11-09 2006-12-20 Univ Cambridge Tech Differentiation of pluripotent cells
JP2010510227A (ja) 2006-11-20 2010-04-02 プレジデント アンド フェロウズ オブ ハーバード カレッジ 痛みおよび痒みの治療方法、組成物およびキット
JP5419279B2 (ja) 2007-01-17 2014-02-19 ウィスコンシン アラムニ リサーチ ファンデーション 改良された幹細胞の培養
KR20100121499A (ko) 2008-02-06 2010-11-17 고리츠다이가쿠호진 요코하마시리츠다이가쿠 세포 배양 방법 및 스크리닝 방법
CN101550406B (zh) 2008-04-03 2016-02-10 北京大学 制备多潜能干细胞的方法,试剂盒及用途
WO2009155301A2 (en) 2008-06-17 2009-12-23 The Mclean Hospital Corporation Multipotent neural cells
EP2334804B1 (en) * 2008-10-07 2013-12-04 True North Therapeutics, Inc. Co-culture compositions and methods
DK2356218T3 (en) 2008-12-05 2017-08-21 Inserm (Institut Nat De La Santé Et De La Rech Médicale) METHOD AND MEDIUM FOR NEURAL DIFFERENTIZATION OF PLURIPOTENT CELLS
US8642334B2 (en) 2009-02-17 2014-02-04 Memorial Sloan Kettering Cancer Center Methods of neural conversion of human embryonic stem cells
US9487751B2 (en) 2009-06-02 2016-11-08 Cornell University Method to isolate, identify, and use embryonic stem cells directed to forebrain interneuron fate
US10119120B2 (en) 2009-08-12 2018-11-06 Kyoto University Method for inducing differentiation of pluripotent stem cells into neural precursor cells
AU2010306377B2 (en) * 2009-10-13 2015-01-22 Stemcell Technologies Canada Inc. Manipulation of osmolality for differentiating stem cells
ES2539487T3 (es) 2009-11-04 2015-07-01 Cellular Dynamics International, Inc. Reprogramación episómica con compuestos químicos
KR101168053B1 (ko) 2009-11-06 2012-07-24 연세대학교 산학협력단 효율적이고 보편적인 전분화능 줄기세포의 신경세포 분화 유도방법
US9097727B2 (en) 2010-03-03 2015-08-04 Kyoto University Method for diagnosing a protein misfolding disease using nerve cells derived from iPS cells
CN102191221B (zh) 2010-03-17 2014-11-19 中国人民解放军第二军医大学东方肝胆外科医院 一种能无限自我更新的神经干细胞、其制备方法及其用途
US20130108669A1 (en) 2010-04-16 2013-05-02 The Mclean Hospital Corporation Dopaminergic neurons differentiated from pluripotent stem cells and uses of thereof
AU2011258634B2 (en) 2010-05-25 2015-03-26 Memorial Sloan-Kettering Cancer Center Method of nociceptor differentiation of human embryonic stem cells and uses thereof
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
EP2582795B1 (en) 2010-06-15 2017-04-12 Kyoto University Method for selecting human induced pluripotent stem cells
CN101935635A (zh) * 2010-07-30 2011-01-05 中国人民解放军第二军医大学 人骨髓多能干细胞的体外扩增和向多巴胺能神经元定向分化的方法
US8883502B2 (en) 2010-09-09 2014-11-11 The Regents Of The University Of California Expandable cell source of neuronal stem cell populations and methods for obtaining and using them
CA2836483C (en) 2011-05-20 2020-08-18 The Mclean Hospital Corporation Neuronal progenitor cells and uses
KR101331034B1 (ko) 2011-06-09 2013-11-19 연세대학교 산학협력단 미분화 줄기세포로부터 중뇌특이적 도파민 신경세포의 제조 방법
US20150086481A1 (en) 2011-07-28 2015-03-26 Memorial Sloan-Kettering Cancer Center Diagnosis and treatment of parkinson's disease
US10280398B2 (en) * 2011-11-04 2019-05-07 Memorial Sloan-Kettering Cancer Center Midbrain dopamine (DA) neurons for engraftment
US10472607B2 (en) 2011-12-14 2019-11-12 National Chung Hsing University Culture medium and method for inducing differentiation of pluripotent stem cells into neuroepithelial cells
EP2614829A1 (en) 2012-01-11 2013-07-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Mammalian neural plate border stem cells capable of forming neural tube and neural crest cell lineages including central and peripheral neurons
CN102604894B (zh) 2012-02-29 2014-07-30 中国科学院广州生物医药与健康研究院 用于制备神经干细胞的培养基及其用途
MX368315B (es) 2012-04-24 2019-09-27 Int Stem Cell Corporation Derivación de células madre neurales y neuronas dopaminérgicas a partir de células madre pluripotentes humanas.
SG11201505152PA (en) 2012-12-28 2015-08-28 Univ Kyoto Method for inducing astrocytes
US10039794B2 (en) 2013-02-15 2018-08-07 International Stem Cell Corporation Use of neural cells derived from human pluripotent stem cells for the treatment of neurodegenerative diseases
US20140248696A1 (en) 2013-03-01 2014-09-04 Wisconsin Alumni Research Foundation Methods of maintaining, expanding, and diffrentiating neuronal subtype specific progenitors
AU2014253960B2 (en) 2013-04-16 2020-06-18 Memorial Sloan-Kettering Cancer Center Age-modified cells and methods for making age-modified cells
CA2910394A1 (en) 2013-04-26 2014-10-30 Memorial Sloan-Kettering Cancer Center Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells
CN105849255A (zh) 2013-09-05 2016-08-10 国立大学法人京都大学 新的产多巴胺神经前体细胞诱导方法
US10220117B2 (en) 2013-10-09 2019-03-05 The Regents Of The University Of California Methods of mammalian retinal stem cell production and applications
KR102483685B1 (ko) 2013-11-21 2023-01-03 메모리얼 슬로안 케터링 캔서 센터 인간 다능성 줄기 세포로부터 기능적 두개 기원판 유도체의 전문화
US9694036B2 (en) 2014-03-21 2017-07-04 Cellular Dynamics International, Inc. Production of midbrain dopaminergic neurons and methods for the use thereof
WO2015143622A1 (zh) 2014-03-25 2015-10-01 云南中科灵长类生物医学重点实验室 一种建立神经上皮干细胞的培养基、方法及其应用
CN107109367B (zh) 2014-10-24 2021-08-10 大日本住友制药株式会社 神经组织的制备方法
WO2016162747A2 (en) 2015-04-09 2016-10-13 Biolamina Ab Methods and compositions for producing stem cell derived dopaminergic cells for use in treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
AU2012332269A1 (en) 2014-05-22
JP6756786B2 (ja) 2020-09-16
ES2779453T3 (es) 2020-08-17
JP2023027064A (ja) 2023-03-01
IL232450A0 (en) 2014-06-30
AU2018222997A1 (en) 2018-09-20
AU2021218116A1 (en) 2021-09-09
JP6461602B2 (ja) 2019-01-30
US11970712B2 (en) 2024-04-30
IL232450B (en) 2020-04-30
BR122020000182B8 (pt) 2022-05-24
IL286793B (en) 2022-09-01
US20200407680A1 (en) 2020-12-31
KR102115273B1 (ko) 2020-05-28
JP2021000104A (ja) 2021-01-07
KR20140116063A (ko) 2014-10-01
CN113528442A (zh) 2021-10-22
AU2018222997B2 (en) 2021-05-20
CN104379731A (zh) 2015-02-25
WO2013067362A1 (en) 2013-05-10
JP2014532440A (ja) 2014-12-08
KR20200061414A (ko) 2020-06-02
IL273910B (en) 2021-10-31
KR102426327B1 (ko) 2022-08-01
US10711243B2 (en) 2020-07-14
BR112014010776B1 (pt) 2021-11-30
JP7225163B2 (ja) 2023-02-20
CN110684734A (zh) 2020-01-14
KR20220108208A (ko) 2022-08-02
EP2773748B1 (en) 2019-12-25
IL273910A (en) 2020-05-31
EP2773748A1 (en) 2014-09-10
CN110684733A (zh) 2020-01-14
EP2773748A4 (en) 2015-04-08
IL295556A (en) 2022-10-01
CN113481159A (zh) 2021-10-08
EA201490796A1 (ru) 2014-10-30
US20150010514A1 (en) 2015-01-08
JP2020178695A (ja) 2020-11-05
EP3693455A1 (en) 2020-08-12
PL2773748T3 (pl) 2020-06-15
CA2854578A1 (en) 2013-05-10
JP2019010104A (ja) 2019-01-24
DK2773748T3 (da) 2020-03-16
JP2017212989A (ja) 2017-12-07
HK1201879A1 (en) 2015-09-11
AU2012332269B2 (en) 2018-05-31
CA3177246A1 (en) 2013-05-10
BR112014010776A8 (pt) 2020-03-17
US10280398B2 (en) 2019-05-07
PT2773748T (pt) 2020-03-26
KR102581669B1 (ko) 2023-09-22
KR20230136702A (ko) 2023-09-26
CA2854578C (en) 2023-01-03
BR112014010776A2 (pt) 2017-04-25
IL286793A (en) 2021-10-31
JP6588500B2 (ja) 2019-10-09
US20190211306A1 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
BR122020000182B1 (pt) Neurônios dopaminérgicos do mesencéfalo para enxerto
Chen et al. The simulated microgravity enhances the differentiation of mesenchymal stem cells into neurons
WO2011149762A3 (en) Method of nociceptor differentiation of human embryonic stem cells and uses thereof
BR112014018524A8 (pt) Derivados de pirimido [4,5-b]indol, seus usos, composição farmaceutica, e método in vivo ou ex vivo para aumentar as células estaminais e/ou progenitoras
Supeno et al. IGF-1 acts as controlling switch for long-term proliferation and maintenance of EGF/FGF-responsive striatal neural stem cells
BR112015011158A2 (pt) triazolopirazina
CL2015002567A1 (es) Compuestos y sus usos para modular la hemoglobina
IN2015DN01616A (pt)
BR112015001620A2 (pt) composição de meio de cultura, e método para cultivo de célula ou tecido usando-se dita composição
BR112015022770A2 (pt) métodos e materiais para diferenciação hematoendotelial de células-tronco pluripotentes humanas sob condições definidas
Koslow et al. ROCK inhibitor increases proacinar cells in adult salivary gland organoids
UY31728A (es) Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-a]piridinas, su preparación y su aplicación en terapéutica
BR112016007853A2 (pt) método de produção de célula epitelial de pigmento retinal
EP3943092A3 (en) Compositions for use in inducing differentiation of human brown adipocyte progenitors
UY31729A (es) Derivados polisustituidos de 2-heteroaril-6-fenil-imidazo[1,2-a]piridinas, su preparación y su aplicación en terapeútica
BR112019004353A2 (pt) métodos e vetores para tratar distúrbios do cns
WO2013063305A3 (en) Directed cardiomyocyte differentiation of stem cells
MX2019015321A (es) Composiciones tridimensionales de tejido y métodos de uso.
BR112013028257A2 (pt) "composição de fármaco biológico, métodos de manipulação de uma composição de fármaco biológica com células vivas e de fornecer composições de células vivas em um ponto de instalação de tratamento, bem como uso de células vivas formuladas em tampão não nutritivo"
BR112015030431A2 (pt) formulação de liberação modificada
BR112015015341A2 (pt) composições para permeabilização de células sanguíneas fixadas e usos das mesmas
SG11201900986YA (en) Alleviation and treatment of ischemia reperfusion-induced lung injury using pluripotent stem cells
BR112015031416A2 (pt) métodos para a promoção do desenvolvimento e/ou da saúde neuronal compreendendo a administração de uma combinação de ácido docosa-hexaenoico e ácido alfa-lipoico
WO2012164008A9 (en) Method of evaluation of the effect of nanoparticles on cell cultures
Seo et al. Adipose-derived stem cell conditioned medium accelerates keratinocyte differentiation via the upregulation of miR-24

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/11/2012, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2676 DE 19/04/2022 QUANTO AO QUADRO REIVINDICATORIO.